Skip to main content
    X

    Xenetic Biosciences Inc (XBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.01
    -0.09 (-4.29%)

    Market Cap: $4.92M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    66%(19/29)
    Avg Surprise
    -5.19%
    Streak
    4 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 6
    		$-0.41N/AN/ABeat+8.9%
    Mar 26
    Reported May 12
    		$-0.20N/AN/ABeat+66.2%
    Dec 25
    Reported Mar 12
    		$-0.22N/A+57.69%Beat+67.6%
    Sep 25
    Reported Nov 12
    		$-0.33$-0.49+32.65%Beat-17.9%
    Jun 25
    Reported Aug 12
    		$-0.45$-0.64+29.69%Beat+45.8%
    Mar 25
    Reported May 13
    		$-0.59$-0.72+18.06%Beat+24.4%
    Dec 24
    Reported Mar 18
    		$-0.68$-0.20-240.00%Miss+11.7%
    Sep 24
    Reported Nov 12
    		$-0.28$-0.14-100.00%Miss+59.4%
    Jun 24
    Reported Aug 13
    		$-0.83$-0.83+0.00%Beat-20.3%
    Mar 24
    Reported May 9
    		$-0.78$-0.79+1.27%Beat-30.0%
    Dec 23
    Reported Mar 21
    		$-0.77$-0.87+11.49%Beat-670.0%
    Sep 23
    Reported Nov 10
    		$-0.69$-1.12+38.39%Beat-15.0%
    Jun 23
    Reported Aug 11
    		$-0.69$-1.13+38.94%Beat+63.7%
    Mar 23
    Reported May 11
    		$-0.60$-1.10+45.45%Beat+50.0%
    Dec 22
    Reported Mar 23
    		$-0.10$-0.09-11.11%Miss+28.6%
    Sep 22
    Reported Nov 10
    		$-0.60N/A+66.67%Beat+53.8%
    Jun 22
    Reported Aug 12
    		$-1.90$-1.20-58.33%Miss-46.2%
    Mar 22
    Reported May 12
    		$-1.20$-1.10-9.09%Miss+20.0%
    Dec 21
    Reported Mar 22
    		$-0.14$-0.15+6.67%Beat+12.5%
    Sep 21
    Reported Nov 12
    		$-1.30$-1.20-8.33%Miss+8.5%
    Jun 21
    Reported Aug 12
    		$-1.30$-1.60+18.75%Beat+13.3%
    Mar 21
    Reported May 12
    		$-1.50$-1.30-15.38%Miss+21.1%
    Dec 20
    Reported Mar 16
    		$-0.16$-0.20+20.00%Beat+20.0%
    Sep 20
    Reported Nov 12
    		$-1.42$-1.30-9.23%Miss+46.8%
    Jun 20
    Reported Aug 12
    		$-1.50$-2.20+31.82%Beat-476.9%
    Mar 20
    Reported May 14
    		$-1.90$-3.70+48.65%Beat-630.8%
    Dec 19
    Reported Mar 26
    		$-0.20$-0.38+47.37%Beat+90.4%
    Sep 19
    Reported Nov 15
    		$-2.67N/AN/ABeat-926.9%
    Jun 19
    Reported Aug 15
    		$-0.26N/AN/ABeat+0.0%
    Mar 19
    Reported May 10
    		$-0.26N/AN/ABeat+0.0%
    Dec 18
    Reported Mar 29
    		$-2.09N/AN/ABeat-704.5%
    Sep 18
    Reported Nov 9
    		$-0.26N/AN/ABeat+99.2%
    Jun 18
    Reported Aug 10
    		$-0.26N/AN/ABeat+99.4%
    Mar 18
    Reported May 15
    		$-0.26$0.00N/ABeat+99.4%
    Dec 17
    Reported Mar 30
    		$-0.26$0.00N/ABeat+96.2%
    Sep 17
    Reported Nov 15
    		$-31.20$-49.20+36.59%Beat-
    Jun 17
    Reported Aug 14
    		$-40.80$-46.80+12.82%Beat-
    Mar 17
    Reported Apr 3
    		$-40.80$-25.20-61.90%Miss-
    Dec 16
    Reported Mar 31
    		$-6.84$-2.28-200.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-1.73EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-75.90%Operating Margin-147.10%
    ROE-47.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio7.43xQuick Ratio7.43x
    Trading Statistics
    Beta2.20Avg Volume155.39K
    52-Week High$4.9452-Week Low$1.87

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.13
    SMA 20$2.31
    SMA 50$3.13
    SMA 200$2.86
    EMA 10$2.16
    EMA 20$2.40
    EMA 50$2.80
    EMA 200$2.94

    MACD

    Line: -0.32Signal: -0.33Hist: 0.01

    ADX

    ADX: 37.5+DI: 14.2-DI: 34.6

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down16.0
    PSAR$2.66

    Bollinger Bands

    Upper Band$2.81
    Lower Band$1.81
    %B Position4299%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    32.1

    Momentum Oscillators

    Stoch %K15.0
    Stoch %D10.1
    Williams %R-78.8
    ROC (10d)-10.3%
    Momentum-0.23
    CCI (20d)-120.4
    MFI (14d)17.4

    Volatility Measures

    ATR (14d)$0.24(11.7%)
    StdDev (20d)0.25
    Hist Vol83.6%(High)

    Volume Flow

    VWAP$2.00
    OBV47.4M
    AD Line-26.8M
    CMF (20d)0.237

    Volume Metrics

    Avg Vol (20d)61.6K
    Vol Ratio0.8x
    VWMA (20d)$2.57

    Pivot Points

    R3$2.21
    R2$2.17
    R1$2.14
    Pivot Point$2.10
    S1$2.07
    S2$2.03
    S3$2.00

    Advanced Oscillators

    TSI-30.40
    Ultimate Osc38.3
    KST-351.60

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$660,601$806,923$766,296$1.03M$589,897$593,261$648,820$614,243$726,404$510,816$671,963$611,174
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Gross Profit$660,601$806,923$766,296$1.03M$589,897$593,261$648,820$614,243$726,404$510,816$671,963$611,174
    Operating Expenses$1.63M$1.31M$1.39M$1.57M$1.31M$1.54M$1.75M$1.11M$2.06M$1.78M$1.93M$1.76M
    R&D$552,013$661,443$773,416$756,482$656,557$879,029$1.04M$367,985$933,771$944,321$975,628$1.02M
    SG&A$1.08M$647,597$615,907$815,209$657,752$656,641$705,710$745,731$1.13M$834,910$952,002$737,241
    Operating Income$-971,690$-502,117$-623,027$-544,734$-724,412$-942,409$-1,099,145$-499,473$-1,337,396$-1,268,414$-1,255,670$-1,146,685
    Interest Income$42,067$45,756$43,792$30,783$34,232$39,190$51,867$61,298$63,447$73,249$83,757$91,796
    Interest Expense$0$0$0$0$0$0$0$0$0$58,621$58,621$0
    Income Before Tax$-929,695$-456,382$-579,076$-509,939$-688,703$-903,141$-1,054,521$-436,671$-1,273,970$-1,195,113$-1,171,506$-1,055,555
    Income Tax Expense$0$0$0$0$0$-10,624$0$-436,671$-18,980$10,624$7,849$-99,436
    Net Income$-929,695$-456,382$-579,076$-509,939$-688,703$-903,141$-1,054,521$-436,671$-1,273,970$-1,195,113$-1,171,506$-1,055,555
    EBITDA$-929,695$-456,382$-579,076$-509,939$-688,703$-903,141$-1,099,145$-436,671$-1,273,970$-1,195,113$-1,255,670$-1,047,915
    EBIT$-971,690$-502,117$-623,027$-509,939$-724,412$-1,109,769N/AN/A$-1,356,380$-1,268,414$-1,299,482$-1,055,555
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XBIO

    News

    Xenetic partner doses first patient in DNase CAR T-cell study

    Xenetic Biosciences, Inc. announced that its partner, PeriNess Ltd., has dosed the first patient in a clinical study combining systemic recombinant human DNase with anti-CD19 CAR T-cell therapy for large B-cell lymphoma....

    Investing.com India•10/15/26•Bullish

    Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

    Xenetic Biosciences and PeriNess Ltd. announced the dosing of the first patient in an investigator-initiated clinical study at Tel Aviv Sourasky University Medical Center. This study evaluates systemic recombinant human...

    FinancialContent•10/15/26•Neutral

    A lymphoma patient is first in a 12-person study to get a DNA-cutting enzyme with immune-cell cancer treatment.

    Xenetic Biosciences announced that the first patient has been dosed in an investigator-initiated clinical study at Tel Aviv Sourasky University Medical Center. The study evaluates the combination of systemic recombinant...

    Stock Titan•10/15/26•Bullish

    Xenetic Biosciences doses first patient in DNase and CAR T-cell study

    Xenetic Biosciences announced that its partner, PeriNess Ltd., has dosed the first patient in a clinical study combining systemic recombinant human DNase with anti-CD19 CAR T-cell therapy for large B-cell lymphoma...

    StreetInsider•10/15/26•Bullish

    Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

    Xenetic Biosciences and PeriNess announced that the first patient has been dosed in an investigator-initiated clinical study at Tel Aviv Sourasky University Medical Center. The study evaluates systemic recombinant human...

    Yahoo Finance•10/15/26•Bullish

    XBIO Valuation and Fair Value

    P/E
    -1.7x
    PEG
    0.0x
    P/B
    0.8x
    See GNG's fair value

    XBIO Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -147.1%
    Net margin
    -75.9%
    ROE
    -47.0%
    FCF margin
    -70.9%

    XBIO Competitors

    CompanyTicker
    Cardio Diagnostics Holdings IncCDIO
    Gelteq Limited Ordinary SharesGELS
    Kala Pharmaceuticals IncKALA
    Intelligent Bio Solutions Inc.INBS
    Biomx IncPHGE
    XTL Biopharmaceuticals Ltd ADRXTLB
    Sonnet Biotherapeutics Holdings IncSONN
    Redhill Biopharma LtdRDHL

    Sector: Healthcare

    XBIO Bull Case vs Bear Case

    Bull case

    • XBIO grew quarterly revenue 12.0% year over year.

    Bear case

    • XBIO has a -75.9% net profit margin.

    XBIO Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    -25.1%

    Frequently Asked Questions About XBIO

    Does XBIO pay dividends?

    Xenetic Biosciences Inc (XBIO) does not currently pay a regular dividend.

    What is XBIO's market cap?

    Xenetic Biosciences Inc (XBIO) has a market capitalization of $4.92M with a current stock price of $2.01.

    Related stocks

    Sector: Healthcare

    All stocks starting with X

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In